Experiences with
Cobimetinib5 public posts
BOLO: New melanoma trial coming from China
IN10018 will be tested as a monotherapy and in combination with Roche's MEK inhibitor Cotellic (cobimetinib), which was approved to treat melanoma in 2015.
Want to take advantage of all our features? Just log in!
or
BRAF/MEK combo raises risk of cardiovascular adverse events compared to BRAF monotherapy only
Three BRAF inhibitors -- dabrafenib, vemurafenib, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.